NCT05478720View on ClinicalTrials.gov

DON in Pediatric Cerebral Malaria

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

August 16, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Malaria, Cerebral
Interventions
DRUG

6-diazo-5-oxo-L-norleucine (DON)

Single intravenous dose ranging from 0.1-10 mg/kg per dose

DRUG

Placebo

Single intravenous dose of saline

DRUG

6-diazo-5-oxo-L-norleucine (DON)

Single intravenous dose ranging from 0.1-1.0 mg/kg per dose

Trial Locations (2)

Unknown

COMPLETED

Ndirande Research Clinic, Blantyre

RECRUITING

Queen Elizabeth Central Hospital, Blantyre

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Douglas Postels, MD, MS

UNKNOWN